Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of “Buy” from Analysts

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has received a consensus recommendation of “Buy” from the six brokerages that are presently covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a buy rating. The average 1 year target price among brokerages that have covered the stock in the last year is $42.83.

DNTH has been the topic of several recent analyst reports. Raymond James raised their price objective on shares of Dianthus Therapeutics from $34.00 to $51.00 and gave the company an “outperform” rating in a research report on Thursday, April 18th. Stifel Nicolaus initiated coverage on Dianthus Therapeutics in a research report on Thursday, February 15th. They issued a “buy” rating and a $44.00 price objective on the stock. Jefferies Financial Group lifted their target price on Dianthus Therapeutics from $22.00 to $39.00 and gave the company a “buy” rating in a research note on Friday, March 22nd. Wedbush upped their price target on Dianthus Therapeutics from $33.00 to $38.00 and gave the stock an “outperform” rating in a research note on Friday, May 10th. Finally, HC Wainwright initiated coverage on shares of Dianthus Therapeutics in a research report on Thursday. They set a “buy” rating and a $40.00 price objective on the stock.

Institutional Trading of Dianthus Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DNTH. Tower Research Capital LLC TRC purchased a new stake in Dianthus Therapeutics in the fourth quarter valued at $25,000. Citigroup Inc. purchased a new stake in shares of Dianthus Therapeutics in the 3rd quarter valued at about $53,000. Acadian Asset Management LLC acquired a new stake in shares of Dianthus Therapeutics in the 3rd quarter valued at about $303,000. Laurion Capital Management LP purchased a new position in Dianthus Therapeutics during the 3rd quarter worth approximately $497,000. Finally, Hussman Strategic Advisors Inc. acquired a new position in Dianthus Therapeutics during the first quarter worth approximately $630,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Trading Down 0.9 %

DNTH opened at $27.69 on Thursday. Dianthus Therapeutics has a 1-year low of $6.58 and a 1-year high of $33.77. The firm’s 50 day simple moving average is $25.60 and its two-hundred day simple moving average is $18.72. The company has a market capitalization of $812.70 million, a PE ratio of -4.75 and a beta of 1.77.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Thursday, March 21st. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.11) by $0.40. The firm had revenue of $0.46 million during the quarter, compared to analysts’ expectations of $0.73 million. Equities analysts forecast that Dianthus Therapeutics will post -2.29 earnings per share for the current fiscal year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.